412 Rec'd PCT/PTO 2 2 MAY 2000

FILING BY "EXI	PRESS MAIL" UNDER 37 CFR
EK127386170US	22 May 2000
Express Mail Label Number	Date of Deposit

(REV 10-96)		S-30287A							
TRANSMITTAL LETTER TO 1	THE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)							
DESIGNATED/ELECTED O		TBAO / E E L O L 1							
CONCERNING A FILING UN		TB 09 /55494 1							
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED							
EP 98/07792	1 December 1998 (01.12.98)	3 December 1997 (03.12.97)							
TITLE OF INVENTION PROTEINASE INHIBITOR FUSION PROTEINS									
APPLICANT(S) FOR DO/EO/US									
ATKINSON et al.									
Applicant herewith submits to the United States D	esignated/Elected Office (DO/EO/US) th	ne following items and other information:							
until the expiration of the applicable time A proper Demand for International Preliments of the International Application as a. is transmitted herewith (required b. has been transmitted by the International Application of the Inte	ubmission of items concerning a filing univariant procedures (35 U.S.C. 371(f)) and PCT A minary Examination was made by the 19th siling items (35 U.S.C. 371(c)) and PCT A minary Examination was made by the 19th siling items (35 U.S.C. 371(c)). Items (35 U.S.C. 371(c)) are mational Bureau. (See Form PCT/IB/30 in was filed in the United States Receiving tion into English (35 U.S.C. 371(c)(2)). Items (35 U.S.C. 371(c)(2)). Items (35 U.S.C. 371(c)(2)) are donly if not transmitted by the International Bureau. Items (35 U.S.C. 371(c)(d)) are made. Items (35 U.S.C. 371(d)(d)) (35 U.S.C. 371(d)) (35 U.	at any time rather than delay examination rticles 22 and 39(1). The month from the earliest claimed priority all Bureau). By g Office (RO/US). (35 U.S.C.371(c)(3)). The has NOT expired.							
Items 11. to 16. below concern document(s) or	r information included.								
11. An Information Disclosure Statement un	der 37 CFR 1.97 and 1.98.								
12. An assignment document for recording.	A separate cover sheet in compliance w	with 37 CFR 3.28 and 3.31 is included.							
13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT prelimina	ary amendment.								
14. A substitute specification.									
15. ☐ A change of power of attorney and/or ad	ldress letter.								

16.

Other items or information: BIBLIOGRAPHIC DATA SHEET

526 Rec'd PCT/PTO 22 MAY 2000

	TION NO. (if known, se	e 37 CFR 1.5)		INTERNATIONAL APPLICATION NO. EP 98/07792 S-30287A		CKET NUN	IBER			
TBA								CALCU	LATIONS	PTO USE ONLY
17. 🔯 T BASIC N	he following fee	s are submitt (<mark>37 CFR 1.4</mark> 9	ed:)2(a) (1)-(5)):					<u></u>		
Se	earch Report has	s been prepai	red by the EP	O or JPO			\$840			
Int	International preliminary examination fee paid to USPTO (37 CFR 1.482) \$670									
 No	No intermetional preliminary examination fee paid to USPTO (37 CFR 1.482)									
bu	but international search fee paid to USPTO (37 CFR 1.445(a)(2))									
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970										
ln ⁱ ar	ternational prelir nd all claims sati	minary exami sfied provisio	nation fee pa ons of PCT Ar	id to USPTO (37 CFR 1.4 ticle 33(2)-(4)	182) 		\$96			
l l							\$	840		
Surcharg	ge of \$130 for fu from the earliest	rnishing the o	oath of declar	ation later than 20 CFR 1.492(e)).	□ 30			\$		
	CLAIMS	NUMBE	R FILED	NUMBER EXTRA		RATE	40			
Fotal cla		17	- 20 =	0	X	\$	18	\$		
Indepen	dent claims	2	- 3 =	0	X	\$	78	\$		
MULTIP	LE DEPENDEN	T CLAIM(S)	(if applicable)		+	\$	260	\$	040	
5:1				TOTAL OF ABOVE	CAL	CULATIC	NS =	\$	840	
- Reductio	on of 1/2 for filing	n by small en	tity, if applica	ble. Verified Small Entity	Statem	ent must a	lso be			
∰educiid ≅filed (No	ote 37 CFR 1.9,	1.27. 1.28).						\$		
illed (140	10 07 01 11 1101	,,_,,				SUBTO	TAL =	\$	840	
=Process	ing fee of \$130 est claimed prio	for furnishing	the English t	ranslation later than	20 [30 montl	ns from +	\$		
Fire Cam	est ciaimod pho	nily date (c.	(,,	TOT	AL NA	TIONAL	FEE =	\$	840	
	P . 11	alacad agaig	nmont (37 CE	R 1.21(h)). The assignment	ent mu	st be accor	npanied			
Eee for	recording the er	iciosed assig	111111111 (37 CF). \$40 per property			· +	\$	40	
	ppropriate cover	sneet (37 Cr	-K 3.20, 3.31	TOTAL F	FES E	NCLOS	ED =	\$	880	
				IVIALI				Ama:	unt to be:	\$
TŲ.									refunded	*
									charged	\$
2 27									Jilaigou	7
a. 🗌	A check in the	amount of \$_		to cover the above f			the amoi	int of \$8	80 to cove	er the above
b. 🛚	b. Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$880 to cover the above fees. A duplicate copy of this form is enclosed.									
c. 🛚	c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis Corporation.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
Send all correspondence to the address associated with Customer No. 022847, which is currently:							Men	M		
Larry W. Stults Novartis Agribusiness Biotechnology Research Inc. Patent Department P.O. Poy 13257 Reg. No. 38,241							t /			
	P.O. Box 12257 Reg. No. 38,241 Research Triangle Park, NC 27709-2257 (919) 541-8587									